Cross-Sector entity
Society for Family Planning is most often covered alongside 5th U.S. Circuit Court of Appeals, which appears in 3 of these 3 stories. The clearest coverage concentration is court-decisions: 1 of 3 stories, with the rest divided among 2 other categories.
3 verified stories tracked
Last mentioned: Sep 9, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Society for Family Planning is most often covered alongside 5th U.S. Circuit Court of Appeals, which appears in 3 of these 3 stories. The clearest coverage concentration is court-decisions: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Society for Family Planning, all published on September 9, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Society for Family Planning. Shared-story counts are live from our verified record — not editorial picks.
5th Circuit hears mifepristone arguments
Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
Louisiana pill access estimated at 770–900 monthly
A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
Supreme Court allows states to decide abortion issue
The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.
A Fifth Circuit panel is weighing whether federal courts or the FDA should govern mifepristone prescribing, with state shield laws and cross-border pill access at issue. The case is one of three appeals seeking to restrict medication abortion.
Medication abortion accounts for at least 60% of U.S. abortions, and a lawsuit could restrict mifepristone prescribing in states where abortion is legal. Clinicians and telehealth providers face uncertainty over cross-border prescriptions and FDA rules.
For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.
Source: MedPage Today · chicagotribune.com
